156(top 1%)
papers
6.4K(top 1%)
citations
38(top 1%)
h-index
79(top 1%)
g-index
179
all documents
7.0K
doc citations
1.1K
citing journals

Top Articles

#TitleJournalYearCitations
1Mutations driving CLL and their evolution in progression and relapseNature2015868
2Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialLancet Haematology,the2016442
3Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trialBlood2014428
4Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trialLancet Haematology,the2017258
5Recurrent mutations refine prognosis in chronic lymphocytic leukemiaLeukemia2015253
6Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemiaBlood2014244
7Precision oncology for acute myeloid leukemia using a knowledge bank approachNature Genetics2017229
8Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trialLancet Oncology, The2017219
9Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndromeBlood2013208
10Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapyBlood2014204
11Clinical and prognostic relevance of the Kiel classification of non‐Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study GroupHematological Oncology1984198
12High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterationsBlood2012179
13ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretationLeukemia2018149
14Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemiaHaematologica2019144
15Requirement for CDK6 in MLL-rearranged acute myeloid leukemiaBlood2014139
16Mutual exacerbation of peroxisome proliferator‐activated receptor γ coactivator 1α deregulation and α‐synuclein oligomerizationAnnals of Neurology2015112
17Comparative analysis of KRAS codon 12, 13, 18, 61 and 117 mutations using human MCF10A isogenic cell linesScientific Reports2015111
18Venetoclax and obinutuzumab in chronic lymphocytic leukemiaBlood2017108
19Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 StudyJournal of Clinical Oncology202174
20Higher-order connections between stereotyped subsets: implications for improved patient classification in CLLBlood202172
21Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemiaLeukemia201669
22NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSGBlood201368
23Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemiaLeukemia201464
24Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33Journal of Experimental Medicine201263
25Analysis of 11q22–q23 deletion target genes in B-cell chronic lymphocytic leukaemia: Evidence for a pathogenic role of NPAT, CUL5, and PPP2R1BEuropean Journal of Cancer200762
26Unified classification and risk-stratification in Acute Myeloid LeukemiaNature Communications202261
27From Biology to Therapy: The CLL Success StoryHemaSphere201955
28Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trialsLeukemia202155
29Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disordersBrain, Behavior, and Immunity200953
30Molecular map of chronic lymphocytic leukemia and its impact on outcomeNature Genetics202252
31CD5+ B cells from individuals with systemic lupus erythematosus express granzyme BEuropean Journal of Immunology201051
32RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemiaLeukemia201851
33IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemiaBlood201951
34CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signalingJournal of Clinical Investigation201347
35Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trialLeukemia202247
36Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemiaLeukemia Research201546
37KIT mutations confer a distinct gene expression signature in core binding factor leukaemiaBritish Journal of Haematology201044
38Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG)Haematologica202044
39Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic LeukemiaHaematologica201542
40Discovery of Candidate DNA Methylation Cancer Driver GenesCancer Discovery202142
41The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemiaBlood202240
42HOXA/PBX3 knockdown impairs growth and sensitizes cytogenetically normal acute myeloid leukemia cells to chemotherapyHaematologica201339
43Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemiaNature Communications201739
44The Differential Diagnosis and Treatment of Thrombotic MicroangiopathiesDeutsches Ärzteblatt International201839
45Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study groupLeukemia201738
46CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemiaLeukemia201938
47A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) TrialBlood202136
48Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1Haematologica202031
49Telomere shortening leads to earlier age of onset in ALS miceAging201631
50Prognostic markers and standard management of chronic lymphocytic leukemiaHematology American Society of Hematology Education Program201529